CMN Weekly (4 July 2021)

Some of the best links we picked up around the internet

By: Karen O'Hanlon Cohrt - Jul. 4, 2021

Top picks

Clinical news

Industry

Research

  • A team of U.S. scientists has developed a CRISPR-based method with the goal of studying how eukaryotic cells repair DNA in space. The rationale behind the work is that astronauts travelling beyond outside the Earth’s magnetosphere are at an increased risk of DNA damage from ionising radiation. The new method uses Cas9 to create precise DNA breaks so that DNA repair pathways can be studied in more detail than would be possible using random DNA damage protocols such as radiation. The results were published in PLOS ONE this week.
  • A team at Brigham and Women’s Hospital (Boston) and collaborators has developed a designer yeast probiotic to help the management of inflammatory bowel disease. The probiotic was developed using CRISPR-Cas9 to introduce genes that could sense inflammation and respond to it by secreting an enzyme with anti-inflammatory activity. Preclinical results with the new probiotic, dubbed Y-bots' (yeast robots), were published in Nature Medicine this week.
  • Scientists at the University of Texas at Austin have developed a series of PEGylated chitosan/CRISPR-Cas9 dry powders for pulmonary delivery via thin-film freeze-drying. The results were published online ahead of print in the International Journal of Pharmaceutics.

Webinars and events

  • In case you missed them, you can catch CRISPR Medicine News webinars on-demand with a CMN+ subscription. Check out our webinar list here and read more about CMN+ benefits here.
  • CRISPR Tsunami: A 1-day introductory course to computational Cas9-gRNA design takes place virtually on 10th September 2021. The course is run by the University of Copenhagen, Denmark, doesn’t assume prior knowledge about gRNA design and is free of charge. Read more about it here.

Reviews

Podcasts and tidbits

  • In the latest episode of The Readout LOUD,” STAT’s biotech podcast, George Yancopoulos, head scientist at Regeneron Pharmaceuticals, talks about the future of CRISPR genome editing.
  • Fighting Cancer with CRISPR: A snappy 10 min video from Bloomberg TV explaining the transformation currently taking place in healthcare and biotech industries involving CRISPR.

Tags

HashtagArticleHashtagMissing linksHashtagNewsHashtagCMN Weekly

CLINICAL TRIALS
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Non-small Cell Lung Cancer,NSCLC, (NCT03525782)
Sponsors:
First Affiliated Hospital of Guangdong Pharmaceutical University
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Prostate Cancer, (NCT03525652)
Sponsors:
The First Affiliated Hospital of Guangdong Pharmaceutical University
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
View all clinical trials
close
Search CRISPR Medicine